Efficacy and safety of drug-eluting beads bronchial arterial chemoembolization versus conventional bronchial arterial chemoembolization in lung cancer patients with hemoptysis-Reference-Cited by-同舟云学术

Efficacy and safety of drug-eluting beads bronchial arterial chemoembolization versus conventional bronchial arterial chemoembolization in lung cancer patients with hemoptysis

Published:2022-08 Issue:25 Volume:18 Page:2805-2815
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Fu Zhigang¹,Wang Chunyan²,Wei Wei³,Xiang Guangming⁴,Guan Li⁴,Zhan Ming⁴,Li Wentian⁴,Peng Xiaogang⁴,Gong Zheng⁴,Gao Baoan⁴^ORCID

Affiliation:

1. Department of Interventional Radiology, Yichang Central People's Hospital, First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, China

2. Department of Emergency, Yichang Central People's Hospital, First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, China

3. Department of Interventional Radiology, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, 443003, China

4. Institute of Respiratory Disease, Yichang Central People's Hospital, First College of Clinical Medical Science, China Three Gorges University, Yichang, 443003, China

Abstract

Background: This study aimed to explore the efficacy and safety of drug-eluting beads bronchial arterial chemoembolization (DEB-BACE) compared with conventional bronchial arterial chemoembolization (cBACE) in lung cancer patients with hemoptysis. Materials & methods: Thirty-six lung cancer patients with hemoptysis treated by DEB-BACE or cBACE were retrospectively analyzed. Results: Technical success of BACE and clinical success of hemoptysis treatment were no different between DEB-BACE and cBACE (both p > 0.050), whereas DEB-BACE achieved increased total clinical response (p = 0.021), objective response rate (p = 0.035) and prolonged hemoptysis relapse-free survival (p = 0.013) compared with cBACE. The adverse event rates were similar between these two groups (all p > 0.05). Conclusion: DEB-BACE presents with higher tumor treatment response, prolonged hemoptysis relapse-free survival and comparable safety profiles compared with cBACE in lung cancer patients with hemoptysis.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2021-1515

Reference16 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Management of hemoptysis in patients with lung cancer

3. Endobronchial Stent Insertion to Manage Hemoptysis caused by Lung Cancer

4. Bronchial artery embolization for hemoptysis: Immediate and long-term results

5. Bronchial Artery Embolization for Hemoptysis in Primary Lung Cancer: A Retrospective Review of 84 Patients

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bronchial artery chemoembolization in the treatment of refractory central lung cancer with atelectasis;Frontiers in Oncology;2024-06-12

2. Role of drug-eluting bead bronchial arterial chemoembolisation in the treatment of non-small cell lung cancer: protocol for a meta-analysis;BMJ Open;2024-06

3. Machine Learning Classifier for Preoperative Prediction of Early Recurrence After Bronchial Arterial Chemoembolization Treatment in Lung Cancer Patients;Academic Radiology;2023-12

4. Drug-eluting beads bronchial arterial chemoembolization vs. conventional bronchial arterial chemoembolization in the treatment of advanced non-small cell lung cancer;Frontiers in Medicine;2023-08-03

5. Efficacy and safety of CalliSpheres drug-eluting beads for bronchial arterial chemoembolization for refractory non-small-cell lung cancer and its impact on quality of life: A multicenter prospective study;Frontiers in Oncology;2023-04-14